SPY457.40+6.90 1.53%
DIA346.61+6.15 1.81%
IXIC15,381.32+127.27 0.83%

BRIEF-Alkermes Announces First Subject Dosed In Phase 1 Study Of of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

reuters.com · 11/11/2021 07:02
BRIEF-Alkermes Announces First Subject Dosed In Phase 1 Study Of of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders

- Alkermes Plc ALKS:

  • ALKERMES ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1 STUDY OF ALKS 1140 FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS

Source text for Eikon: ID:nPn7bpNzMa

Further company coverage: ALKS


((Reuters.Briefs@thomsonreuters.com;;))